MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

A research team has made further progress in the treatment of intestinal inflammation. A study shows that the semi-synthetic bile acid NorUDCA inhibits in the intestine the formation of ...

Crohn's disease belongs to a group of conditions known as inflammatory bowel diseases (IBD). This chronic condition causes ...

Pliant Therapeutics, Inc.’s PLRX share price has surged by 10.39%, which has investors questioning if this is right time to sell.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report)‘s stock had its “neutral” rating restated by HC Wainwright in a research ...

AlphaQuest LLC lowered its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 73.9% during the 4th quarter, ...

Crohn’s disease is an autoimmune disease and a type of inflammatory bowel disease (IBD). If you have one autoimmune disease, like Crohn’s, you are more likely to have another autoimmune disease.

Bile duct inflammation and scarring, known as cholangiopathies, can disrupt bile flow, leading to liver damage and ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).